SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Carmona L, Hernandez-Garcia C, Vadillo C, Pato E, Balsa A, Gonzalez-Alvaro I, et al. Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol 2003; 30: 14369.
  • 2
    Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Coster L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 2005; 52: 198692.
  • 3
    Yamada T, Nakajima A, Inoue E, Tanaka E, Hara M, Tomatsu T, et al. Increased risk of tuberculosis in patients with rheumatoid arthritis in Japan. Ann Rheum Dis 2006; 65: 16613.
  • 4
    Seong SS, Choi CB, Woo JH, Bae KW, Joung CL, Uhm WS, et al. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol 2007; 34: 70611.
  • 5
    Bouza E, Moya JG, Munoz P. Infections in systemic lupus erythematosus and rheumatoid arthritis. Infect Dis Clin North Am 2001; 15: 33561.
  • 6
    Brassard P, Kezouh A, Suissa S. Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis 2006; 43: 71722.
  • 7
    Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab: a tumor necrosis factor α-neutralizing agent. N Engl J Med 2001; 345: 1098104.
  • 8
    Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004; 50: 3729.
  • 9
    Statistics Canada. Chiffres de population et des logements, Canada, provinces et territoires, recensements de 2006 et 2001: données intégrales. URL: http://www12.statcan.ca/francais/census06/data/popdwell/Table.cfm.
  • 10
    World Health Organization. International statistical classification of diseases, injuries, and causes of death: ninth revision (ICD-9). Geneva: WHO; 1977.
  • 11
    Le Comité Quebecois sur la Tuberculose. Epidemiologie de la tuberculose au Quebec (1992–1995, 1996–1999, 2000–2003). Quebec City: Sante Publique; 2005.
  • 12
    Suissa S. Novel approaches to pharmacoepidemiology study design and statistical analysis. New York: John Wiley & Sons; 2000.
  • 13
    American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000; 161: S22147.
  • 14
    Institut de la Statistique du Quebec. Estimation de la population des régions administratives par groupe d'âge et sexe, 1er juillet des années 1996 à 2007. URL: http://www.stat.gouv.qc.ca/donstat/societe/demographie/index.htm.
  • 15
    SAS software: version 9.1. Cary (NC): SAS Institute; 2004.
  • 16
    Phypers M, Kunimoto D, Behr M, Scholten D, Ellis E. Epidemiology of tuberculosis in Canada. In: LongR, EllisE, editors. Canadian tuberculosis standards. 6th ed. Ottawa: Public Health Agency of Canada; 2007. p. 114.
  • 17
    Selwyn PA, Hartel D, Lewis VA, Schoenbaum EE, Vermund SH, Klein RS, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989; 320: 54550.
  • 18
    Bieber J, Kavanaugh A. Cigarette smoking, TB, and TNF inhibitors [letter]. Ann Rheum Dis 2003; 62: 11189.
  • 19
    Falagas ME, Voidonikola PT, Angelousi AG. Tuberculosis in patients with systemic rheumatic or pulmonary diseases treated with glucocorticosteroids and the preventive role of isoniazid: a review of the available evidence. Int J Antimicrob Agents 2007; 30: 47786.
  • 20
    Jick SS, Lieberman ES, Rahman MU, Choi HK. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum 2006; 55: 1926.
  • 21
    Singh JA, Holmgren AR, Noorbaloochi S. Accuracy of Veterans Administration databases for a diagnosis of rheumatoid arthritis. Arthritis Rheum 2004; 51: 9527.
  • 22
    Curtis JR, Martin C, Saag KG, Patkar NM, Kramer J, Shatin D, et al. Confirmation of administrative claims-identified opportunistic infections and other serious potential adverse events associated with tumor necrosis factor α antagonists and disease-modifying antirheumatic drugs. Arthritis Rheum 2007; 57: 3436.
  • 23
    Ernst P, Gonzalez AV, Brassard P, Suissa S. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007; 176: 1626.
  • 24
    Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Bijlsma JW, et al. Updated consensus statement on biological agents, specifically tumour necrosis factor α (TNFα) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004. Ann Rheum Dis 2004; 63 Suppl 2: ii212.
  • 25
    Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003; 3: 14855.
  • 26
    Centers for Disease Control and Prevention. Tuberculosis associated with blocking agents against tumor necrosis factor-α: California, 2002–2003. MMWR Morb Mortal Wkly Rep 2004; 53: 6836.
  • 27
    British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-α treatment. Thorax 2005; 60: 8005.
  • 28
    Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59: 76284.